Drug intelligence / Profile preview

mesalazine + ursodeoxycholic acid

Development stage: Preclinical
Lead developer: Tillotts Pharma
Modality: Small Molecules
Administration: Oral

Overview

A combination therapy consisting of mesalazine and ursodeoxycholic acid (UDCA). This combination has shown better therapeutic effects than mesalazine alone in patients with ulcerative colitis, possibly due to changes in the IL-23-IL-17 axis and beneficial alterations in intestinal microflora distribution. The combination therapy results in lower levels of inflammatory markers and improved clinical outcomes as measured by Mayo scores and Inflammatory Bowel Disease Questionnaire scores.

Targets

IBABP (Ileal bile acid-binding protein)

Beyond the preview

Go deeper on mesalazine + ursodeoxycholic acid.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on mesalazine + ursodeoxycholic acid.

Explore the full profile